AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 earnings, which were highlighted by the pivotal execution phase following the strategic combination of Atai Life Sciences and Beckley Psytech and its subsequent US redomiciliation. A primary focus is the BPL-003 nasal spray for treatment-resistant depression/TR, which is on track to initiate a Phase 3 pivotal program in Q2 2026. This program, supported by the FDA, will include two major studies, ReConnection-1 and ReConnection-2, with topline results anticipated by early 2029.

The company also reported positive clinical progress across its broader pipeline, including the VLS-01 buccal film and EMP-01 for Social Anxiety Disorder/SAD. VLS-01 is expected to yield Phase 2 topline data in H2 2026. Meanwhile, an exploratory Phase 2a trial of EMP-01 successfully met its primary safety objectives and showed clinically meaningful improvements in efficacy measures. To protect these innovations, AtaiBeckley secured a new US patent for EMP-01, extending its expected exclusivity through 2043.

AtaiBeckley Inc. (NASDAQ:ATAI) ended 2025 with $220.7 million in cash, cash equivalents, and short-term securities driven by equity-related issuances. While the company reported a net loss of $660 million for the full year, largely due to a $530 million non-cash charge related to the Beckley Psytech acquisition, it maintains a strong capital position. Management expects current liquidity to fund operations into early 2029, covering the timeline for its major Phase 3 readouts.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.